DOCSLIB.ORG

Isoliquiritigenin Inhibits Proliferation and Metastasis of MKN28 Gastric Cancer Cells by Suppressing the PI3K/AKT/Mtor Signaling Pathway

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Isoliquiritigenin Inhibits Proliferation and Metastasis of MKN28 Gastric Cancer Cells by Suppressing the PI3K/AKT/Mtor Signaling Pathway MOLECULAR MEDICINE REPORTS 18: 3429-3436, 2018 Isoliquiritigenin inhibits proliferation and metastasis of MKN28 gastric cancer cells by suppressing the PI3K/AKT/mTOR signaling pathway XIU-RONG ZHANG1,2, SHI-YAO WANG3, WEN SUN4 and CHAO WEI5 1Department of Traditional Chinese Medicine, Maternal and Child Health Care of Shandong Province; 2Key Laboratory of Birth Regulation of National Health and Family Planning Commission of China, Jinan, Shandong 250014; 3Department of Chinese Medicine, The Second Clinical Medical College of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong 510000; 4Department of Research, Beijing Splinger Medical Research Institute, Jinan, Shandong 250021; 5Department of Ophthalmology, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China Received November 3, 2017; Accepted June 19, 2018 DOI: 10.3892/mmr.2018.9318 Abstract. Isoliquiritigenin (ISL) is a flavonoid extracted from following ISL pretreatment, thus suggesting that ISL triggered licorice root, which is known to serve important antitumor autophagy in MKN28 cells. In addition, the phosphorylation roles in numerous types of cancers; however, its effect on levels of protein kinase B (AKT) and mammalian target of gastric cancer remains to be elucidated. The present study rapamycin (mTOR) were significantly reduced following ISL aimed to explore the roles and underlying mechanisms of ISL treatment. These results indicated that ISL may influence in MKN28 gastric cancer cells. MKN28 cell proliferation apoptosis and autophagy in MKN28 cells by suppressing the was measured using the Cell Counting Kit‑8 (CCK8) assay. phosphoinositide 3‑kinase/AKT/mTOR signaling pathway. In A Transwell assay was used to determine the effects of ISL conclusion, the findings of the present study suggested that ISL on the migration and invasion of MKN28 cells. Apoptosis may inhibit MKN28 cell proliferation, migration and invasion was assessed by flow cytometry, and the expression levels of by inducing apoptosis and autophagy, implying potential as a apoptosis‑, autophagy‑ and signaling pathway‑related proteins therapeutic agent for gastric cancer. were detected by western blot analysis. The results of the CCK8 assay demonstrated that ISL significantly inhibited Introduction the proliferation of MKN28 cells (P<0.05). Transwell assays demonstrated that the migration and invasion of MKN28 Gastric cancer is the fourth most prevalent cancer world- cells were significantly inhibited following treatment with wide (1,2) and the second leading cause of cancer‑associated ISL (P<0.05). Flow cytometric analysis indicated that ISL mortality (3). Despite the important advances in cancer induced apoptosis of MKN28 cells. In addition, western blot therapy, gastric cancer remains a major malignancy and a analysis revealed that the ratio of microtubule‑associated serious threat to human health (4). Surgical, radiotherapeutic proteins 1A/1B light chain 3B (LC3)II/LC3I was upregulated, and chemotherapeutic strategies have recently become as was Beclin 1 expression; however, p62 was downregulated available for the treatment of gastric cancer (5); however, radiotherapy and chemotherapy exert severe adverse effects, and the development of drug resistance is common. Therefore, it is necessary to develop novel, effective and safe agents for the treatment of gastric cancer. Recently, natural Correspondence to: Dr Wen Sun, Department of Research, Beijing Splinger Medical Research Institute, 685 Jingsi Road, Huaiyin, products have attracted attention. Studies have reported Jinan, Shandong 250021, P.R. China that compounds from natural resources are suitable alterna- E‑mail: [email protected] tives for controlling cancer with minimal toxicity and high efficacy (6‑8). Dr Chao Wei, Department of Ophthalmology, The Second Hospital Isoliquiritigenin (ISL) is a flavonoid with a chalcone of Shandong University, 247 Beiyuan Road, Jinan, Shandong 250033, P.R. China structure that is derived from licorice compounds (9,10). It E‑mail: [email protected] is found ubiquitously in foods and beverages, and tobacco. ISL has been reported to exhibit a wide range of distinct Key words: isoliquiritigenin, MKN28 cells, proliferation, biological properties and pharmacological activities, including phosphoinositide 3‑kinase/protein kinase B/mammalian target of anti‑inflammatory, anti‑oxidation, antiplatelet aggregation, rapamycin, apoptosis, autophagy cardioprotective effects against ischemia‑reperfusion, and estrogenic properties (11‑13). ISL has also been reported to suppress the proliferation and to induce the apoptosis of 3430 ZHANG et al: ISL INHIBITS PROLIFERATION AND METASTASIS OF GASTRIC CANCER MKN28 CELLS numerous cancers in vitro and in vivo (14), including colon and and washed with PBS at room temperature. Subsequently, breast cancer (15‑18). images were captured and the cells in five random fields were At present, the anticancer effects and underlying mecha- counted manually using light microscopy. nisms of ISL on gastric cancer have not been fully elucidated. The migration assay was similar to the invasion assay, with The present study conducted a series of preliminary experiments the exception that the Transwell system was not coated with to suggest that ISL may inhibit the proliferation, migration and Matrigel, and the number of cells tested was 5,000. invasion of MKN28 gastric cancer cells, which may be associ- ated with phosphoinositide 3‑kinase (PI3K)/protein kinase B Apoptosis analysis. Following treatment with 20 µM ISL or (AKT)/mammalian target of rapamycin (mTOR) signaling 0.1% DMSO (control group) for 24 h, cells were collected and pathway‑mediated apoptosis and autophagy. digested with trypsin (Beijing Solarbio Science & Technology Co., Ltd.). Cells were then washed using precooled PBS (4˚C). Materials and methods The cell density was adjusted to 1‑5x106/ml by adding 1X binding buffer. Subsequently, 100‑µl cell suspension was placed Cell culture and treatment. The MKN28 human gastric cancer in a 5 ml flow tube, and 5 µl Annexin V/fluorescein isothio- cell line and the GES‑1 human gastric normal epithelial cyanate (FITC; BD Biosciences, Franklin Lakes, NJ, USA) was mucosa cell line were purchased from the Cell Bank of the added and mixed by flicking the tube for 5 min in the dark at Chinese Academy of Sciences (Shanghai, China). The cells room temperature, followed by incubation with 10 µl propidium were cultured in RPMI‑1640 medium supplemented with 10% iodide for 10‑15 min in the dark room at room temperature. (v/v) fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Following this, 400 µl PBS was added and mixed, and the tubes Waltham, MA, USA), penicillin (100 U/ml) and streptomycin were subsequently placed on ice. The results were detected (0.1 mg/ml; both Sigma‑Aldrich; Merck KGaA, Darmstadt, using a flow cytometer (BD Biosciences) in 1 h and analyzed Germany) and incubated at 37˚C in a humidified atmosphere using FlowJo v10.0 software (FlowJo LLC, Ashland, OR, USA). containing 5% CO2. When the cells entered the logarithmic growth phase, they were washed with PBS three times, and Western blot analysis. To extract proteins, cells in the were then digested by trypsin (Beijing Solarbio Science & experimental and NC groups were added to 6‑well plates Technology Co., Ltd., Beijing, China). Once the cells became and treated with radioimmunoprecipitation assay lysis buffer rounded, the digestion was terminated and the cells were (CW Biotech, Beijing, China) plus protease inhibitor. Protein placed in culture medium, after which they were pipetted into concentration was measured using a Bicinchoninic Acid 6‑well plates for subsequent experiments. When cell conflu- Protein Assay kit (CW Biotech), after which the proteins ence in the wells reached ~80%, the cells were treated with were heated for 5 min at 95˚C. Vertical electrophoresis was ISL (MedChemExpress, Monmouth Junction, NJ, USA) or performed with ~20 µg protein in each lane. The proteins 0.1% dimethyl sulfoxide (DMSO; Amresco, LLC, Solon, OH, were isolated by 10% SDS‑PAGE and transferred onto poly- USA) as a negative control (NC). vinylidene fluoride membranes. The membranes were blocked with 5% skim milk powder at room temperature for 1 h and Cell Counting Kit‑8 (CCK8) proliferation detection. CCK-8 were incubated with primary antibodies overnight at 4˚C. (Beijing Solarbio Science & Technology Co., Ltd. Beijing, The following rabbit anti‑human primary antibodies were China) was used to assess the effects of ISL on MKN28 and used: AKT (1:1,000; cat. no. 9272; Cell Signaling Technology, GES‑1 cell proliferation. MKN28 or GES‑1 cells (100 µl) Inc., Danvers, MA, USA), phosphorylated (p‑)AKT (1:1,000; were seeded into 96‑well plates at a cellular density of cat. no. 4060; Cell Signaling Technology, Inc.), mTOR 1,000 cells/well. To the NC group, 0.1% DMSO was added, (1:1,000; cat. no. 2972; Cell Signaling Technology, Inc.), whereas 20 µM ISL was added to the experimental group. p‑mTOR (1:1,000; cat. no. 2971; Cell Signaling Technology, Cells were cultured for 0, 24, 48 and 72 h time intervals at Inc.), B‑cell lymphoma 2 (Bcl‑2; 1:1,000; cat. no. 4223; Cell 37˚C, and the cell viabilities at each time interval were subse- Signaling Technology, Inc.), caspase‑3 (1:1,000; cat. no. 9664; quently detected. Prior to detection, 10 µl CCK8 solution was Cell Signaling Technology, Inc.), Bcl‑2‑associated X protein added to each well for 1.5 h at 37˚C. The optical density (OD) (Bax; 1:1,000; cat. no. 5023; Cell Signaling Technology, value was measured at 450 nm using a microplate reader to Inc.), microtubule‑associated proteins 1A/1B light chain 3B obtain the proliferation curve. (LC3; 1:1,000; cat. no. 14600‑1‑AP; ProteinTech Group, Inc., Chicago, IL, USA), Beclin 1 (1:1,000; cat. no. 11306‑1‑AP; Transwell migration and invasion assays. For the invasion ProteinTech Group, Inc.), p62 (1:1,000; cat. no. 5114; Cell assay, the inner layer of a 24‑well Transwell system (EMD Signaling Technology, Inc.) and GAPDH (1:5,000; cat. Millipore, Billerica, MA, USA) was pre‑coated with Matrigel no.
Load more

Recommended publications
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short
    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Active Recombinant MAPKAPK3
    RESEARCH USE ONLY Active Recombinant MAPKAPK3 CATALOG NO.: JM-7755-5 AMOUNT: 5 μg BACKGROUND: MAPKAPK3 has a single potential SH3-binding site in the proline-rich N terminus, a putative ATP- binding site, 2 MAP kinase phosphorylation site motifs, and a putative nuclear localization signal. It shares 72% nucleotide and 75% amino acid identity with MAPKAPK2 (1). MAPKAPK3 was shown to be activated by growth inducers and stress stimulation of cells. In vitro studies demonstrated that ERK, p38 MAP kinase and Jun N-terminal kinase were all able to phosphorylate and activate this kinase, which suggested the role of this kinase as an integrative element of signaling in both mitogen and stress responses (2). This kinase was reported to interact with, phosphorylate and repress the activity of E47, which is a basic helix-loop-helix transcription factor known to be involved in the regulation of tissue-specific gene expression and cell differentiation (3). MAPKAPK3 is uniquely poised to support luteal maturation through the phosphorylation and activation of the nuclear transcription factor CREB (4). DESCRIPTION: Recombinant full length human MAPKAPK3 containing N-terminal GST tag was expressed by baculovirus in Sf 9 insect cells. The gene accession number is NM_004635. PURITY: 1.5 μg of MAPKAPK3 protein was subjected to SDS-PAGE and Coomassie blue staining. The scan of the blue gel showed >90% purity of the MAPKAPK3 protein product, and the band was at ~69 kDa (Fig. 2). FORMULATION: Recombinant proteins in storage buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, 25% glycerol).
    [Show full text]
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • The Use of Phosphoproteomic Data to Identify Altered Kinases and Signaling Pathways in Cancer
    The use of phosphoproteomic data to identify altered kinases and signaling pathways in cancer By Sara Renee Savage Thesis Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Biomedical Informatics August 10, 2018 Nashville, Tennessee Approved: Bing Zhang, Ph.D. Carlos Lopez, Ph.D. Qi Liu, Ph.D. ACKNOWLEDGEMENTS The work presented in this thesis would not have been possible without the funding provided by the NLM training grant (T15-LM007450) and the support of the Biomedical Informatics department at Vanderbilt. I am particularly indebted to Rischelle Jenkins, who helped me solve all administrative issues. Furthermore, this work is the result of a collaboration between all members of the Zhang lab and the larger CPTAC consortium. I would like to thank the other CPTAC centers for processing the data, and Chen Huang and Suhas Vasaikar in the Zhang lab for analyzing the colon cancer copy number and proteomic data, respectively. All members of the Zhang lab have been extremely helpful in answering any questions I had and offering suggestions on my work. Finally, I would like to acknowledge my mentor, Bing Zhang. I am extremely grateful for his guidance and for giving me the opportunity to work on these projects. ii TABLE OF CONTENTS Page ACKNOWLEDGEMENTS ................................................................................................ ii LIST OF TABLES............................................................................................................
    [Show full text]
  • Inhibition of ERK 1/2 Kinases Prevents Tendon Matrix Breakdown Ulrich Blache1,2,3, Stefania L
    www.nature.com/scientificreports OPEN Inhibition of ERK 1/2 kinases prevents tendon matrix breakdown Ulrich Blache1,2,3, Stefania L. Wunderli1,2,3, Amro A. Hussien1,2, Tino Stauber1,2, Gabriel Flückiger1,2, Maja Bollhalder1,2, Barbara Niederöst1,2, Sandro F. Fucentese1 & Jess G. Snedeker1,2* Tendon extracellular matrix (ECM) mechanical unloading results in tissue degradation and breakdown, with niche-dependent cellular stress directing proteolytic degradation of tendon. Here, we show that the extracellular-signal regulated kinase (ERK) pathway is central in tendon degradation of load-deprived tissue explants. We show that ERK 1/2 are highly phosphorylated in mechanically unloaded tendon fascicles in a vascular niche-dependent manner. Pharmacological inhibition of ERK 1/2 abolishes the induction of ECM catabolic gene expression (MMPs) and fully prevents loss of mechanical properties. Moreover, ERK 1/2 inhibition in unloaded tendon fascicles suppresses features of pathological tissue remodeling such as collagen type 3 matrix switch and the induction of the pro-fbrotic cytokine interleukin 11. This work demonstrates ERK signaling as a central checkpoint to trigger tendon matrix degradation and remodeling using load-deprived tissue explants. Tendon is a musculoskeletal tissue that transmits muscle force to bone. To accomplish its biomechanical function, tendon tissues adopt a specialized extracellular matrix (ECM) structure1. Te load-bearing tendon compart- ment consists of highly aligned collagen-rich fascicles that are interspersed with tendon stromal cells. Tendon is a mechanosensitive tissue whereby physiological mechanical loading is vital for maintaining tendon archi- tecture and homeostasis2. Mechanical unloading of the tissue, for instance following tendon rupture or more localized micro trauma, leads to proteolytic breakdown of the tissue with severe deterioration of both structural and mechanical properties3–5.
    [Show full text]
  • PRODUCTS and SERVICES Target List
    PRODUCTS AND SERVICES Target list Kinase Products P.1-11 Kinase Products Biochemical Assays P.12 "QuickScout Screening Assist™ Kits" Kinase Protein Assay Kits P.13 "QuickScout Custom Profiling & Panel Profiling Series" Targets P.14 "QuickScout Custom Profiling Series" Preincubation Targets Cell-Based Assays P.15 NanoBRET™ TE Intracellular Kinase Cell-Based Assay Service Targets P.16 Tyrosine Kinase Ba/F3 Cell-Based Assay Service Targets P.17 Kinase HEK293 Cell-Based Assay Service ～ClariCELL™ ～ Targets P.18 Detection of Protein-Protein Interactions ～ProbeX™～ Stable Cell Lines Crystallization Services P.19 FastLane™ Structures ～Premium～ P.20-21 FastLane™ Structures ～Standard～ Kinase Products For details of products, please see "PRODUCTS AND SERVICES" on page 1～3. Tyrosine Kinases Note: Please contact us for availability or further information. Information may be changed without notice. Expression Protein Kinase Tag Carna Product Name Catalog No. Construct Sequence Accession Number Tag Location System HIS ABL(ABL1) 08-001 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) BTN BTN-ABL(ABL1) 08-401-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ABL(ABL1) [E255K] HIS ABL(ABL1)[E255K] 08-094 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) HIS ABL(ABL1)[T315I] 08-093 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) [T315I] BTN BTN-ABL(ABL1)[T315I] 08-493-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ACK(TNK2) GST ACK(TNK2) 08-196 Catalytic domain
    [Show full text]
  • Identification of Key Genes and Pathways in Parkinson's Disease Through Integrated Analysis
    MOLECULAR MEDICINE REPORTS 16: 3769-3776, 2017 Identification of key genes and pathways in Parkinson's disease through integrated analysis JINGRU WANG, YINING LIU and TUANZHI CHEN Department of Neurology, Liaocheng People's Hospital, Liaocheng Clinical School of Taishan Medical University, Liaocheng, Shandong 252004, P.R. China Received March 31, 2016; Accepted April 19, 2017 DOI: 10.3892/mmr.2017.7112 Abstract. Parkinson's disease (PD) is a progressive, degene- PD when compared with normal healthy controls. In conclu- rative neurological disease, typically characterized by tremors sion, the results indicate that the significant DEGs, including and muscle rigidity. The present study aimed to identify differe- UCHL1, PDPK1 and PRKACB may be associated with the ntially expressed genes (DEGs) between patients with PD and development of PD. In addition, these factors may be involved healthy patients, and clarify their association with additional in various signaling pathways, including amoebiasis, vascular biological processes that may regulate factors that lead to PD. smooth muscle contraction and the Wnt and calcium signaling An integrated analysis of publicly available Gene Expression pathways. Omnibus datasets of PD was performed. DEGs were identi- fied between PD and normal blood samples. Gene Ontology Introduction enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analyses, as well as protein-protein interaction (PPI) Parkinson's disease (PD) is a chronic, progressive, degene- networks were used to predict the functions of identified DEGs. rative neurological disease, and is the second most common Reverse transcription-quantitative polymerase chain reaction neurodegenerative disease following Alzheimer's disease (1). (RT-qPCR) was performed to validate the predicted expression The clinical symptoms of PD may be motor-associated or levels of identified DEGs in whole blood samples obtained patients may present with non-motor manifestations.
    [Show full text]
  • A Loss-Of-Function Genetic Screening Identifies Novel Mediators of Thyroid Cancer Cell Viability
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 19 A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability Maria Carmela Cantisani1, Alessia Parascandolo2, Merja Perälä3,4, Chiara Allocca2, Vidal Fey3,4, Niko Sahlberg3,4, Francesco Merolla5, Fulvio Basolo6, Mikko O. Laukkanen1, Olli Pekka Kallioniemi7, Massimo Santoro2,8, Maria Domenica Castellone8 1IRCCS SDN, Naples, Italy 2Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universita’ Federico II, Naples, Italy 3Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland 4Center for Biotechnology, University of Turku, Turku, Finland 5Dipartimento di Scienze Biomediche Avanzate, Università Federico II, Naples, Italy 6Division of Pathology, Department of Surgery, University of Pisa, Pisa, Italy 7FIMM-Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland 8Istituto di Endocrinologia ed Oncologia Sperimentale “G. Salvatore” (IEOS), C.N.R., Naples, Italy Correspondence to: Maria Domenica Castellone, e-mail: [email protected] Keywords: kinases, screening, siRNA, thyroid carcinoma Received: October 01, 2015 Accepted: March 02, 2016 Published: April 4, 2016 ABSTRACT RET, BRAF and other protein kinases have been identified as major molecular players in thyroid cancer. To identify novel kinases required for the viability of thyroid carcinoma cells, we performed a RNA interference screening in the RET/PTC1(CCDC6- RET)-positive papillary thyroid cancer cell line TPC1 using a library of synthetic small interfering RNAs (siRNAs) targeting the human kinome and related proteins. We identified 14 hits whose silencing was able to significantly reduce the viability and the proliferation of TPC1 cells; most of them were active also in BRAF-mutant BCPAP (papillary thyroid cancer) and 8505C (anaplastic thyroid cancer) and in RAS-mutant CAL62 (anaplastic thyroid cancer) cells.
    [Show full text]
  • MAPKAP Kinase 3 (MAPKAPK3) (NM 004635) Human Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP300358 MAPKAP Kinase 3 (MAPKAPK3) (NM_004635) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3) Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 42.8 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Bioactivity: MAPKAPK3 activity verified in a biochemical assay: MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase 3) (TP300358) activity was measured in a homogeneous time-resolved fluorescent (HTRF®) assay. MAPKAPK3 is a serine/threonine kinase that functions as a mitogen-activated protein kinase (MAP kinase)- activated protein kinase. Varying concentrations of MAPKAPK3 were added to a reaction mix containing ATP and a biotinylated kinase substrate and the reaction mixture was incubated to allow the protein to phosphorylate the substrate. HTRF detection reagents were then added, and the time- resolved fluorescent signal was measured on a Flexstation 3 microplate reader. The time resolved fluorescent signal is expressed as “delta R” or “ΔR” and is a ratio calculated from the fluorescent emission intensities of the donor and acceptor fluors. Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions.
    [Show full text]
  • Identification of Tumor-Associated Autoantigens for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein Microarrays*□S
    Research Identification of Tumor-associated Autoantigens for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein Microarrays*□S Ingrid Babel‡§, Rodrigo Barderas‡§¶, Ramo´ n Díaz-Uriarteʈ, Jorge Luis Martínez-Torrecuadrada**, Marta Sa´ nchez-Carbayo‡‡, and J. Ignacio Casal‡§§ There is a mounting evidence of the existence of autoan- Colorectal cancer (CRC)1 is the second most prevalent tibodies associated to cancer progression. Antibodies are cancer in the western world. The development of this disease the target of choice for serum screening because of their takes decades and involves multiple genetic events. CRC stability and suitability for sensitive immunoassays. By remains a major cause of mortality in developed countries using commercial protein microarrays containing 8000 because most of the patients are diagnosed at advanced human proteins, we examined 20 sera from colorectal stages because of the reluctance to use highly invasive diag- cancer (CRC) patients and healthy subjects to identify nostic tools like colonoscopy. Actually only a few proteins autoantibody patterns and associated antigens. Forty- have been described as biomarkers in CRC (carcinoembry- three proteins were differentially recognized by tumoral onic antigen (CEA), CA19.9, and CA125 (1–3)), although none and reference sera (p value <0.04) in the protein microar- of them is recommended for clinical screening (4). Proteomics rays. Five immunoreactive antigens, PIM1, MAPKAPK3, analysis is actively used for the identification of new biomar- STK4, SRC, and FGFR4, showed the highest prevalence in kers. In previous studies, the use of two-dimensional DIGE cancer samples, whereas ACVR2B was more abundant in and antibody microarrays allowed the identification of differ- normal sera.
    [Show full text]
  • MAPKAPK3 Sirna Set I MAPKAPK3 Sirna Set I
    Catalog # Aliquot Size M41-911-05 3 x 5 nmol M41-911-20 3 x 20 nmol M41-911-50 3 x 50 nmol MAPKAPK3 siRNA Set I siRNA duplexes targeted against three exon regions Catalog # M41-911 Lot # Z2049-79 Specificity Formulation MAPKAPK3 siRNAs are designed to specifically knock- The siRNAs are supplied as a lyophilized powder and down human MAPKAPK3 expression. shipped at room temperature. Product Description Reconstitution Protocol MAPKAPK3 siRNA is a pool of three individual synthetic Briefly centrifuge the tubes (maximum RCF 4,000g) to siRNA duplexes designed to knock-down human collect lyophilized siRNA at the bottom of the tube. MAPKAPK3 mRNA expression. Each siRNA is 19-25 bases in Resuspend the siRNA in 50 µl of DEPC-treated water length. The gene accession number is NM_004635. (supplied by researcher), which results in a 1x stock solution (10 µM). Gently pipet the solution 3-5 times to mix Gene Aliases and avoid the introduction of bubbles. Optional: aliquot 3PK; 3pK; MAPKAP3 1x stock solutions for storage. Storage and Stability Related Products The lyophilized powder is stable for at least 4 weeks at room temperature. It is recommended that the Product Name Catalog Number lyophilized and resuspended siRNAs are stored at or MAPKAPK2, Active M40-11G below -20oC. After resuspension, siRNA stock solutions ≥2 MAPKAPK2, Active M40-11H µM can undergo up to 50 freeze-thaw cycles without MAPKAPK3, Active M41-10G significant degradation. For long-term storage, it is MAPKAPK5, Active M42-10G recommended that the siRNA is stored at -70oC. For most Anti-MAPKAPK2/3 M40-63R favorable performance, avoid repeated handling and MAPKAPK2, Unactive M40-14G multiple freeze/thaw cycles.
    [Show full text]